COMy 2019 | What is the future for myeloma clinical trials?

Mohamad Mohty

Mohamad Mohty, MD, PhD of Saint-Antoine Hospital, Paris, France, discusses the future of clinical trials for multiple myeloma, including a focus on smoldering myeloma and stopping the evolution of myeloma at an earlier stage, rather than after organ damage. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

Share this video  
Similar topics
Related videos
Myeloma XI trial: increased progression-free survival
Charlotte Pawlyn
Pivotal STORM study: selinexor for penta-refractory multiple myeloma
Joshua Richter
Current challenges for multiple myeloma therapy: 2, 3, 4-drug combinations
Joshua Richter
Multiple myeloma musings: highlights from 2018 data
Joshua Richter
An exciting era for CAR T-cell therapy
Mohamad Mohty
Multiple Myeloma
COMy 2019
Interview
17th May 2019
More from Mohamad Mohty
MRD testing in leukemia, lymphoma and myeloma
CAR T-cell therapy: factors to consider
Mohamad Mohty's myeloma highlights from ASH 2018
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals